Tests arlo-cel against standard treatments in relapsed multiple myeloma
Compares arlo-cel, a cell therapy, with standard treatments in adults with myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Key facts
- Where
- Adelaide, Brisbane, Camperdown, Clayton, Liverpool, Melbourne, and Murdoch, AustraliaSee the 8 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Has a doctor told you that your myeloma can be measured in your blood or urine tests?
- Which describes how well you can look after yourself?
- Has a doctor told you that you have myeloma in the brain or in the fluid and membranes around the brain and spinal cord, now or in the past?
Source: NCT06615479, who can take part
Where in Australia
- AdelaideAdelaide, AustraliaNo longer taking part
- BrisbaneBrisbane, AustraliaNo longer taking part
- CamperdownCamperdown, AustraliaNo longer taking part
- ClaytonClayton, AustraliaNo longer taking part
- LiverpoolLiverpool, AustraliaNo longer taking part
- MelbourneMelbourne, AustraliaNo longer taking part
- MelbourneMelbourne, AustraliaNo longer taking part
- MurdochMurdoch, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06615479EU 2024-515279-37-00
- Record updated
- 29 October 2026
- Original description
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Inclusion: Participants must have relapsed or refractory multiple myeloma (RRMM); Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide; Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria; Participants must have measurable disease during screening; Participants must have adequate organ function; Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.
Exclusion: Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM); Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease; Participants must not need urgent treatment due to rapidly progressing MM; Other protocol-defined Inclusion/Exclusion criteria apply.